A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/00 (2006.01) A61K 9/127 (2006.01) A61K 38/21 (2006.01) A61K 39/38 (2006.01) A61K 45/00 (2006.01) A61K 47/00 (2006.01)
Patent
CA 2421464
Alfa interferon (.alpha.-IFN or alpha-interferon) and liposomal all-trans retinoic acid is useful in cancer treatment with particular reference to renal cancer. Optionally, a regimen of .alpha.-interferon from about 3 to about 5 million units sc daily and liposomal all-trans retinoic acid at from a bout 15 mg/m2 to about 90mg/m2, or about 140mg/m2, or about 300mg/m2 or more. Dosage periodicity of about three times per week for both drugs in about 8 week cycles is useful.
L'invention concerne l'interféron alfa (.alpha.-IFN ou interféron alpha) et l'acide all-trans rétinoïque liposomal utilisés dans le traitement du cancer, notamment du cancer du rein. La composition est éventuellement administrée selon un schéma posologique d'environ 3 à 5 millions d'unités quotidiennes d'.alpha.-interféron, et d'environ 15 mg/m?2¿ à 90mg/m?2¿, ou d'environ 140mg/m?2¿, ou d'environ 300mg/m?2¿ ou plus d'acide all-trans rétinoïque liposomal. La périodicité du dosage utile est d'environ trois fois par semaine pour les deux médicaments dans des cycles d'environ huit semaines.
Aronex Pharmaceuticals Inc.
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Combined interferon alfa and liposomal-encapsulated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combined interferon alfa and liposomal-encapsulated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined interferon alfa and liposomal-encapsulated... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1668521